Physician profile
Jeffry D Meyer
NPI 1336195643
$8,077.24
in general payments reported to CMS, 2019-2025
47 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $1,077 · 2021: $752 · 2022: $1,044 · 2023: $1,589 · 2024: $1,150 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,211 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,211.03 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $818.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $671.41 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $668.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $663.73 | 2019-2025 | |
| Abbvie INC. | $657.22 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $624.14 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Dexcom, INC. | $477.34 | 2019-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $259.52 | 2023-2025 | Veozah, Vyloy, Myrbetriq |
| Merck Sharp & Dohme LLC | $228.93 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Daiichi Sankyo INC. | $215.07 | 2019-2024 | Injectafer |
| Boston Scientific Corporation | $209.69 | 2023-2025 | Watchman Flx, Watchman Access System |
| Amarin Pharma, INC. | $193.79 | 2020-2022 | |
| Mylan Specialty L.P. | $183.93 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $176.60 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $165.92 | 2021-2024 | Xarelto |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffry Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.